In 2020 German biotech companies managed to raise a record sum of more than 3 billion Euro in equity capital. What had the pandemic to do with this and will the corona-virus have a long-term positive impact on the financing of German biotechs? What are the industry expectations from the government? How has the German government addressed the challenges of COVID 19 on the German biotech and VC industry? What drives the IPO activity in the US and Europe in 2021 and are «COVID» stories distorting the picture?
Stefan Fischer, Managing Partner (Finance) of our Mainsponsor TVM Capital Life Science will discuss these and further questions with her panelists:
- Matthias Kromayer, General Partner, MIG
- Christian Stiebner, Investment Manager, KfW Capital
- and Otello Stamapacchia, Managing Director, Omega Funds
The discussion will take place Thursday 28 April starting 1 pm.